JP2017519739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519739A5 JP2017519739A5 JP2016569787A JP2016569787A JP2017519739A5 JP 2017519739 A5 JP2017519739 A5 JP 2017519739A5 JP 2016569787 A JP2016569787 A JP 2016569787A JP 2016569787 A JP2016569787 A JP 2016569787A JP 2017519739 A5 JP2017519739 A5 JP 2017519739A5
- Authority
- JP
- Japan
- Prior art keywords
- gln
- lys
- thr
- leu
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1-hexadecyl Chemical group 0.000 claims 66
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004156P | 2014-05-28 | 2014-05-28 | |
| US62/004,156 | 2014-05-28 | ||
| PCT/US2015/033042 WO2015184177A1 (en) | 2014-05-28 | 2015-05-28 | Improved peptide pharmaceuticals for insulin resistance |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075470A Division JP2020143066A (ja) | 2014-05-28 | 2020-04-21 | インスリン抵抗性のための改善されたペプチド医薬品 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519739A JP2017519739A (ja) | 2017-07-20 |
| JP2017519739A5 true JP2017519739A5 (cg-RX-API-DMAC7.html) | 2018-07-12 |
| JP6697807B2 JP6697807B2 (ja) | 2020-05-27 |
Family
ID=54699825
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569787A Active JP6697807B2 (ja) | 2014-05-28 | 2015-05-28 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2020075470A Pending JP2020143066A (ja) | 2014-05-28 | 2020-04-21 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2022127266A Pending JP2022172128A (ja) | 2014-05-28 | 2022-08-09 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2024067692A Pending JP2024102119A (ja) | 2014-05-28 | 2024-04-18 | インスリン抵抗性のための改善されたペプチド医薬品 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075470A Pending JP2020143066A (ja) | 2014-05-28 | 2020-04-21 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2022127266A Pending JP2022172128A (ja) | 2014-05-28 | 2022-08-09 | インスリン抵抗性のための改善されたペプチド医薬品 |
| JP2024067692A Pending JP2024102119A (ja) | 2014-05-28 | 2024-04-18 | インスリン抵抗性のための改善されたペプチド医薬品 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9856306B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3155017B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6697807B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102542164B1 (cg-RX-API-DMAC7.html) |
| CN (5) | CN106661097A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2015266854B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016027595B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2949701C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3155017T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2985732T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3155017T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE066179T2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL285613B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX384236B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ726623A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3155017T4 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3155017T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015184177A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10010617B2 (en) | 2011-05-18 | 2018-07-03 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
| US10471127B2 (en) | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| BR112015011478B1 (pt) * | 2012-11-20 | 2022-10-25 | Mederis Diabetes, Llc | Produtos de peptídeo, seus usos e composição farmacêutica |
| DK3444281T3 (da) | 2012-11-20 | 2022-02-07 | Eumederis Pharmaceuticals Inc | Forbedrede peptidlægemidler |
| CA2949701C (en) | 2014-05-28 | 2023-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| AU2018302022A1 (en) | 2017-07-17 | 2020-02-27 | Macregen, Inc. | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| IL311775A (en) | 2018-01-03 | 2024-05-01 | Mederis Diabetes Llc | Improved peptide drugs for the treatment of NASH and other disorders |
| AU2021224246A1 (en) * | 2020-02-21 | 2022-09-15 | Spitfire Pharma Llc | GLP-1R and GCGR agonists, formulations, and methods of use |
| JP2024500324A (ja) * | 2020-12-07 | 2024-01-09 | スピットファイア ファーマ エルエルシー | Ｇｌｐ－１ｒおよびｇｃｇｒ均衡アゴニストを使用した血糖および／または体重を低下させるための治療レジメンおよび方法 |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| CN113461747B (zh) * | 2021-07-12 | 2023-02-03 | 吉林化工学院 | 刺玫果中2个具有降血糖活性的化合物 |
| CN121219311A (zh) * | 2023-05-24 | 2025-12-26 | 联邦生物科技(珠海横琴)有限公司 | 一种胰岛素衍生物及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| ES2561985T3 (es) | 2001-10-10 | 2016-03-01 | Ratiopharm Gmbh | Remodelación y glicoconjugación de anticuerpos |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| WO2006096426A2 (en) | 2005-03-03 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| WO2006121860A2 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| US7390788B2 (en) | 2005-06-23 | 2008-06-24 | Pert Candace B | Peptide pharmaceutical compositions |
| ATE448247T1 (de) | 2005-09-22 | 2009-11-15 | Biocompatibles Uk Ltd | Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| PE20140186A1 (es) | 2010-12-22 | 2014-02-13 | Univ Indiana Res & Tech Corp | Analogos de glucagon que presentan actividad de receptor de gip |
| KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
| US10471127B2 (en) | 2011-05-18 | 2019-11-12 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
| US10010617B2 (en) | 2011-05-18 | 2018-07-03 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
| DK3444281T3 (da) * | 2012-11-20 | 2022-02-07 | Eumederis Pharmaceuticals Inc | Forbedrede peptidlægemidler |
| BR112015011478B1 (pt) | 2012-11-20 | 2022-10-25 | Mederis Diabetes, Llc | Produtos de peptídeo, seus usos e composição farmacêutica |
| PL2986313T3 (pl) * | 2013-04-18 | 2019-12-31 | Novo Nordisk A/S | Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych |
| CA2949701C (en) | 2014-05-28 | 2023-12-12 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
| MA55068A (fr) * | 2014-10-24 | 2022-01-05 | Merck Sharp & Dohme | Co-agonistes des récepteurs du glucagon et du glp-1 |
| IL311775A (en) * | 2018-01-03 | 2024-05-01 | Mederis Diabetes Llc | Improved peptide drugs for the treatment of NASH and other disorders |
-
2015
- 2015-05-28 CA CA2949701A patent/CA2949701C/en active Active
- 2015-05-28 US US15/314,466 patent/US9856306B2/en active Active
- 2015-05-28 ES ES15798956T patent/ES2985732T3/es active Active
- 2015-05-28 IL IL285613A patent/IL285613B2/en unknown
- 2015-05-28 PT PT157989567T patent/PT3155017T/pt unknown
- 2015-05-28 NZ NZ726623A patent/NZ726623A/en unknown
- 2015-05-28 FI FIEP15798956.7T patent/FI3155017T3/fi active
- 2015-05-28 EP EP15798956.7A patent/EP3155017B1/en active Active
- 2015-05-28 MX MX2020000201A patent/MX384236B/es unknown
- 2015-05-28 KR KR1020167036463A patent/KR102542164B1/ko active Active
- 2015-05-28 NZ NZ757113A patent/NZ757113A/en unknown
- 2015-05-28 PL PL15798956.7T patent/PL3155017T4/pl unknown
- 2015-05-28 CN CN201580041790.0A patent/CN106661097A/zh active Pending
- 2015-05-28 KR KR1020237018945A patent/KR20230084337A/ko not_active Ceased
- 2015-05-28 KR KR1020247042894A patent/KR20250007694A/ko active Pending
- 2015-05-28 HU HUE15798956A patent/HUE066179T2/hu unknown
- 2015-05-28 JP JP2016569787A patent/JP6697807B2/ja active Active
- 2015-05-28 CN CN202311098620.9A patent/CN117582516A/zh active Pending
- 2015-05-28 BR BR112016027595-0A patent/BR112016027595B1/pt active IP Right Grant
- 2015-05-28 CN CN202011222645.1A patent/CN113264994A/zh active Pending
- 2015-05-28 DK DK15798956.7T patent/DK3155017T3/da active
- 2015-05-28 EP EP24150928.0A patent/EP4397374A3/en active Pending
- 2015-05-28 CN CN202311098595.4A patent/CN117180445A/zh active Pending
- 2015-05-28 WO PCT/US2015/033042 patent/WO2015184177A1/en not_active Ceased
- 2015-05-28 CN CN201910116865.7A patent/CN109865142A/zh active Pending
- 2015-05-28 AU AU2015266854A patent/AU2015266854B2/en active Active
- 2015-05-28 MX MX2016015594A patent/MX371033B/es active IP Right Grant
-
2016
- 2016-11-17 IL IL249044A patent/IL249044B/en active IP Right Grant
-
2017
- 2017-11-21 US US15/820,127 patent/US10577405B2/en active Active
-
2020
- 2020-01-21 US US16/747,759 patent/US20200277351A1/en not_active Abandoned
- 2020-04-21 JP JP2020075470A patent/JP2020143066A/ja active Pending
- 2020-06-02 AU AU2020203609A patent/AU2020203609B2/en active Active
- 2020-06-21 IL IL275526A patent/IL275526B/en unknown
-
2022
- 2022-08-09 JP JP2022127266A patent/JP2022172128A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200659A patent/AU2023200659A1/en active Pending
-
2024
- 2024-04-18 JP JP2024067692A patent/JP2024102119A/ja active Pending
- 2024-11-11 US US18/943,440 patent/US20250136656A1/en active Pending
- 2024-12-19 US US18/988,066 patent/US20250313604A1/en active Pending